Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli
- 1 June 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (6) , 980-985
- https://doi.org/10.1128/aac.29.6.980
Abstract
The in vitro synergistic activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam, combined with ampicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, and apalcillin, were determined against 34 strains of members of the Enterobacteriaceae family, Pseudomonas aeruginosa, Aeromonas hydrophila, and Haemophilus influenzae with characterized plasmid or chromosomal beta-lactamases or both. Strains were tested against fixed concentrations of beta-lactamase inhibitors (8 micrograms/ml) combined with doubling dilutions of beta-lactams. Synergy was defined as a fourfold or greater decrease in the MIC of the beta-lactam. Against Enterobacteriaceae producing Richmond and Sykes class III and V plasmid-mediated beta-lactamases, synergy was obtained against most strains with YTR 830- and clavulanate-beta-lactam combinations, with sulbactam being less effective. Against Enterobacteriaceae producing class I chromosomal beta-lactamases, combinations containing YTR 830 or sulbactam were more synergistic than combinations containing clavulanate. Against strains producing class V PSE enzymes, all three inhibitors were synergistic with piperacillin and apalcillin against strains producing PSE-1, -3, and -4 enzymes, while the PSE-2-producing strain was resistant to all inhibitors. YTR 830-beta-lactam combinations were also synergistic against strains producing the novel beta-lactamases OHIO-1, TLE-1, AER-1, and ROB-1. Overall, YTR 830 with piperacillin or apalcillin was the most effective combination.This publication has 17 references indexed in Scilit:
- Treatment of infections in hospitalized patients with ticarcillin plus clavulanic acid: A comparative studyThe American Journal of Medicine, 1985
- Five novel plasmid-determined beta-lactamasesAntimicrobial Agents and Chemotherapy, 1985
- Genetic and biochemical properties of AER-1, a novel carbenicillin-hydrolyzing beta-lactamase from Aeromonas hydrophilaAntimicrobial Agents and Chemotherapy, 1985
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infectionsAntimicrobial Agents and Chemotherapy, 1984
- beta-Lactamase inhibitory activity of iodopenicillanate and bromopenicillanateAntimicrobial Agents and Chemotherapy, 1983
- Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administrationAntimicrobial Agents and Chemotherapy, 1982
- AMPICILLIN TREATMENT FAILURE OF APPARENTLY β-LACTAMASE-NEGATIVE HAEMOPHILUS INFLUENZAE TYPE b MENINGITIS DUE TO NOVEL β-LACTAMASEThe Lancet, 1981
- Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacaeAntimicrobial Agents and Chemotherapy, 1980
- Combined Activity of Clavulanic Acid and Ticarcillin Against Ticarcillin-Resistant, Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 1978